To improve the efficacy of plasminogen activators, we produced a monoclonal antibody
(RWR) that inhibits human alpha 2-antiplasmin (alpha 2AP). In addition to inhibiting alpha …

Purpose: The advancement of catheter-based interventions for vascular recanalization has
underscored the need for an experimental animal model of vascular thrombosis that can be …

Thrombotic complications of cardiovascular disease are a main cause of death and disability
and, consequently, thrombolysis could favorably influence the outcome of such life …

An unknown epitope of apolipoprotein (a) antagonizes fibrinogen binding to agonist-
stimulated platelet's fibrinogen (GPIIb/IIIa) receptor yielding lipoprotein (a) mediated …

Streptokinase (SK) is an enzyme that is used for the treatment of cardiovascular diseases.
The current study focused on the enhanced production of SK by inducing mutation in …

Abstract Fungi fibrinolytic compound 1 (FGFC1) is a novel marine natural product as a low-
weight fibrinolytic pyranoindole molecule, whose thrombolytic effects were evaluated on …

Urokinase (UK)[EC 3.4. 99.26] is a serine protease that activates plasminogen to plasmin,
which in turn degrades fibrin clots. Hence, UK finds its value as an important anti …

The chimeric molecule K 1 K 2 P u, comprising the two kringle domains (K 1 and K 2) of
tissue-type plasminogen activator (t-PA) and the COOH-terminal region with the serine …

Three children with major intracardiac or vascular thrombosis following cardiac operations
were treated with intravenous recombinant tissue-type plasminogen activator. The first …

The vampire bat salivary plasminogen activator (Bat-PA) is a potent PA that exhibits
remarkable selectivity toward fibrin-bound plasminogen (Gardell et al, J Biol Chem 256 …